NCT02786732TerminatedPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Sponsor
- MedDerm Associates
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- PASI Improvement
Study Overview
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
Detailed Description
The study is up to 5 years. If you qualify, you will be randomized into 1 of 4 groups. Two groups will get brodalumab(1 group will get 210milligrams of brodalumab at each dose and the other group will get 140 milligrams of brodalumab at each dose), one group will get ustekinumab, and one group will get placebo.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject has had stable moderate to severe plaque psoriasis for at least 6 months before first dose of IP.
- •Subject has involved body surface area >_10%, PASI>_, and sPGA>_3 at screening and at baseline.
- •For women, a negative serum pregnancy test during screening a negative urine pregnancy test at baseline.
- •Subject has no known history of active tuberculosis.
- •Subject has a negative test for tuberculosis during screening.
Exclusion Criteria
- •Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at the time of the screening visit that would interfere with evaluations of the effect of IP on psoriasis.
- •Subject has a planned surgical intervention between baseline and the week 52 evaluation.
- •Subject an active infection or history of infections.
- •Subject has any systemic disease considered by the investigator to be clinically significant and uncontrolled.
- •Subject has known history of Crohn's disease.
- •Subject has known history of hepatitis B, hepatitis C, or human immunodeficiency virus.
- •Subject had myocardial infarction or unstable angina pectoris within the past 12 months prior to the first dose of IP.
- •Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
- •Subject has history of malignancy within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
- •Subject has received live vaccine(s) within 28 days of the first dose of IP.
- •Subject has used ustekinumab and/or antio-IL-17 biologic therapy ever or other experimental or commercially available biologi immune modulator(s) within 12weeks prior to the first IP dose
- •Subject currently is enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s).
- •For women not willing to use highly effective methods of birth control during treatment and for 15 weeks after the last dose.
- •For women; pregnant or breast feeding, or planning to become pregnant while enrolled in the study and for 15 weeks after the last dose.
Arms & Interventions
210mg Brodalumab
Experimental
Administered by subcutaneous injection until Week 12
Intervention: 210mg Brodalumab (Biological)
140mg Brodalumab
Experimental
Administered subcutaneous injection until Week 12
Intervention: 210mg Brodalumab (Biological)
Ustekinumab
Active Comparator
Administered subcutaneous injection until Week 52
Intervention: 140mg Brodalumab (Biological)
Placebo
Placebo Comparator
Administered subcutaneous injection until Week 12
Intervention: 210mg Brodalumab (Biological)
Placebo
Placebo Comparator
Administered subcutaneous injection until Week 12
Intervention: Placebo (Biological)
Placebo
Placebo Comparator
Administered subcutaneous injection until Week 12
Intervention: Ustekinumab (Biological)
Outcomes
Primary Outcomes
PASI Improvement
Time Frame: 12 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Michelle Pelle, M.D.
Principal Investigator
MedDerm Associates
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
A Study of TAK-771 in Japanese Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMJPRN-jRCT2051210110ishizawa Atsushi26
Active, not recruiting
Phase 3
A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndromeFamilial Chylomicronemia SyndromeGenetic DiseasesISRCTN12904794Arrowhead Pharmaceuticals, Inc.76
Not yet recruiting
Phase 3
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-Interferon Alfa-2a With Ribavirin in Interferon (IFN) Naive Patients Geno2/3Chronic Hepatits COral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12607000092493Human Genome Sciences, Inc920
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of MarzAA for the control of bleeding episodes in subjects with Haemophilia A or Haemophilia B, with InhibitorsMarzeptacog alfa (activated) (MarzAA), a novel activated recombinant Factor VII (rFVIIa) variant, is being developed by Catalyst Biosciences to address the unmet need in haemophilia and other bleeding disorders.MedDRA version: 20.0Level: LLTClassification code 10066439Term: HemophiliaSystem Organ Class: 100000004850EUCTR2020-000996-19-BGCatalyst Biosciences, Inc.60
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Orally Administered BF2.649 in Japanese Patients with Narcolepsy, Consisting of a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study (Part 1) and Subsequent Open-label Extension Study (Part 2)arcolepsyJPRN-jRCT2031220432chimura Naohisa123